ClinicalTrials.gov
public full text
Public Domain
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study aimed to determine whether decreased α-N-acetylgalactosaminidase levels are associated with psychotic symptoms in methamphetamine users.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Psilocybin for Methamphetamine Addiction#1101744
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: recommendations from the British Association for Psychopharmacology#331664
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.#247477
- What Dose of Methamphetamine Do Regular Consumers Use Daily? Estimating Oral Amphetamine Milligram Equivalents#683831
- Non-Abstinence Outcomes in Methamphetamine Use Disorder#994019
Record · ID 1059638
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive